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Abstract
Background: Schizophrenia, a relatively common psychiatric syndrome, affects virtually all brain
functions yet has eluded explanation for more than 100 years. Whether by developmental and/or
degenerative processes, abnormalities of neurons and their synaptic connections have been the
recent focus of attention. However, our inability to fathom the pathophysiology of schizophrenia
forces us to challenge our theoretical models and beliefs. A search for a more satisfying model to
explain aspects of schizophrenia uncovers clues pointing to genetically mediated CNS
microvascular inflammatory disease.
Discussion:  A vascular component to a theory of schizophrenia posits that the physiologic
abnormalities leading to illness involve disruption of the exquisitely precise regulation of the
delivery of energy and oxygen required for normal brain function. The theory further proposes that
abnormalities of CNS metabolism arise because genetically modulated inflammatory reactions
damage the microvascular system of the brain in reaction to environmental agents, including
infections, hypoxia, and physical trauma. Damage may accumulate with repeated exposure to
triggering agents resulting in exacerbation and deterioration, or healing with their removal.
There are clear examples of genetic polymorphisms in inflammatory regulators leading to
exaggerated inflammatory responses. There is also ample evidence that inflammatory vascular
disease of the brain can lead to psychosis, often waxing and waning, and exhibiting a fluctuating
course, as seen in schizophrenia. Disturbances of CNS blood flow have repeatedly been observed
in people with schizophrenia using old and new technologies. To account for the myriad of
behavioral and other curious findings in schizophrenia such as minor physical anomalies, or
reported decreased rates of rheumatoid arthritis and highly visible nail fold capillaries, we would
have to evoke a process that is systemic such as the vascular and immune/inflammatory systems.
Summary: A vascular-inflammatory theory of schizophrenia brings together environmental and
genetic factors in a way that can explain the diversity of symptoms and outcomes observed. If these
ideas are confirmed, they would lead in new directions for treatments or preventions by avoiding
inducers of inflammation or by way of inflammatory modulating agents, thus preventing exaggerated
inflammation and consequent triggering of a psychotic episode in genetically predisposed persons.
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Background
When the solution to a clinical or scientific puzzle eludes
us for more than a century, as with schizophrenia (for-
merly dementia praecox), we need new ways of thinking
about the problem [1,2]. Efforts to understand schizo-
phrenia have focused on neurons and, especially, the role
of presumed excess dopamine neurotransmission. We
believe that genetic, environmental, and stochastic factors
combine with epigenetic factors to create episodes of the
illness [3-5]. Thus, the syndrome of schizophrenia is
viewed as an endpoint in a dynamic process variously con-
ceptualized as degenerative or developmental or alternat-
ing at different points in the process [6-10].
Degenerative models imply that after a period of normal
development, the organism, or one of its parts, takes a
wrongful turn in its trajectory and begins to malfunction.
This describes the eventual outcome for all life forms and
is a biological restatement of the second law of thermody-
namics. Since degeneration is universal, stating that an ill-
ness is degenerative is not particularly helpful. What
would be helpful is to determine when in the life course
the degeneration begins and how the degeneration is ini-
tiated and proceeds. Answers to the "when?" and "how?"
questions would then describe the degenerative process in
developmental terms.
Developmental models of schizophrenia implicate abnor-
malities of early brain development predisposing to
future schizophrenia. The proponents of the model fur-
ther argue that the perturbations of development are lim-
ited to the early times of development and are
discontinuous. Without this qualifier, developmental
models are indistinguishable from degenerative models
where the degeneration commences early in the life span.
The early abnormalities are not necessarily the cause of
schizophrenia, but, instead, create a state of risk for a
future episode of schizophrenia. That is, a diathesis or pre-
disposition is not a disease. Consequently, there must be
factors later in life that convert the vulnerability to an ill-
ness. These additional factors are presumed to damage
development in such a way that a predisposition becomes
actualized. To gain a complete understanding of the syn-
drome, we must again return to the question of " what
happens?"
Following this line of reasoning, the distinction between
degenerative and developmental models blurs. In fact, a
medical-behavioral condition can be both developmental
and degenerative as exemplified by Down syndrome [11-
13]. Individuals born with trisomy 21 exhibit a number of
developmental anomalies including cardiac malforma-
tions, abnormal dermatoglyphics, skeletal changes, and
muscular hypotonia, to name a few. As trisomy 21 infants
mature, most exhibit degrees of mental retardation. By
about age 50, these individuals invariably develop Alzhe-
imer-like CNS degenerative changes that can be seen at
autopsy [13].
Schizophrenia involves both developmental and degener-
ative features. From the time of Bleuler [14] and Kraepe-
lin[15], "It is certain that many a schizophrenia can be
traced back into the early years of the patient's lives..."
[14] p. 252. The 'follow back' studies of schizophrenia
support these views [16]. Likewise, prospective studies of
children at high risk for schizophrenia report develop-
mental anomalies in motor skills, cognition, and atten-
tion long before the onset of overt illness [17-19]. Overt
psychotic symptoms for some individuals usually start in
the late teenage years or early twenties, but the illness can
start as early as middle childhood [20] and may, more
rarely, start in old age [21] p 73].
The evidence suggesting early developmental perturba-
tions in schizophrenia is compelling. At the same time,
there certainly are examples of deterioration reminiscent
of Kraepelin's suggestion for some people with schizo-
phrenia. However, deterioration in clinical course may
not indicate CNS deterioration. Instead, the decline could
be a secondary consequence of an illness that disrupts
education, economic achievement, and social functioning
leading to a downward spiral in all aspects of adult life.
Consistent with an early degenerative process, there are
reports of declining cognitive function preceding onset of
psychosis [22]. Proponents of neurodevelopmental mod-
els suggest that the premorbid cognitive abnormalities are
developmental risk factors for future schizophrenia (c.f
[23]) and argue that such abnormalities show little evi-
dence of decline after onset [6,24]. Whether developmen-
tal or degenerative, the premorbid cognitive deficits seen
in schizophrenia are also seen in other disorders [25] and
lack specificity and sensitivity thus detracting from the
concept that the cognitive abnormalities seen in schizo-
phrenia are useful endophenotypes [26]. The strongest
evidence for a neurodegenerative phenomenon comes
from imaging studies showing progressive loss of brain
volumes [27-29]. Neuropathological studies fail to find
widespread classic signs of neurodegeneration such as
gliosis though there are exceptions to this generalization
[30]. Observations of abnormal dendritic arborization
[31,32] are consistent with the neuroimaging evidence
suggesting abnormal connectivity between brain regions
[29]. As a cautionary note, most of the neuroimaging and
neuropathology results are subject to confounds from the
effects of medications and various other treatments, post-
mortem intervals, possible effects of diet, smoking habits,
as well as a myriad of other potential confounds associ-
ated with glucocorticoid mediated stress following
chronic illness and associated life's limitations [33,34].BMC Medical Genetics 2005, 6:7 http://www.biomedcentral.com/1471-2350/6/7
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The symptoms of schizophrenia are highly variable.
Within families (and thus presuming relative homogene-
ity of genetic and environmental factors) symptoms can
vary widely over time, as illustrated by identical quadru-
plets concordant for schizophrenia [35]. Even within
affected individuals, symptoms will wax and wane and
may even remit [36] suggesting a life long process.
The major behavioral symptoms of schizophrenia include
alterations in cognition, memory, perception, thought
(inferred from language), motor functions, and affect.
People with schizophrenia may show abnormal derma-
toglyphics and other minor physical anomalies [37-42].
Other oddities to be incorporated in a comprehensive
explanation of schizophrenia include highly visible nail
fold capillaries [43,44] and the rarity of rheumatoid
arthritis among schizophrenic persons [45]. These physi-
cal characteristics suggest the need to look beyond the
nervous system per se to have a comprehensive view of the
illness.
The fact that the schizophrenia syndrome, as currently
defined, is relatively common provides important infor-
mation about the frequency of causal factors. About 1% of
the population will experience schizophrenia during the
lifespan. Except for a few rare exceptions, this 1% risk is
remarkably constant around the globe regardless of cul-
ture, geography, or ethnicity. Men and women are affected
equally. These facts mean that the risk factors for schizo-
phrenia must also be common and ubiquitous. Given that
the concordance rate for schizophrenia in identical twins
[46] is only about 50%, there must be at least two global
risk-increasing categories for schizophrenia, i.e., some-
thing(s) genetic and something(s) environmental.
Assuming these risk factors are independent of each other,
the joint probability of acquiring both risk factors is the
product of their population frequencies that, for schizo-
phrenia, equals about .01. To make a simplifying assump-
tion to allow easy calculations, let us say that the two risk
factors are present with about equal frequency in the pop-
ulation. With this simplification, straightforward mathe-
matics indicates that the individual frequencies of these
factors are close to the square root of the population fre-
quency of 1%. That would mean that about 10% of the
population would encounter at least one risk factor. The
math indicates that the greater the number of independ-
ent risk factors, the more common they are. [See [47] for
further elaboration].
Our challenge is to develop a theory of schizophrenia that
can plausibly explain an illness that affects all domains of
behavior (thought, affect, motor performance, etc), that
has elements of developmental perturbations early in life
leaving clues such as minor physical abnormalities, and
also has elements of degenerative changes. At the same
time, the defect is so subtle that we can't find the cause(s)
with our best modern technology. Furthermore, in spite of
brain-wide dysfunctions, many individuals with schizo-
phrenia remain sufficiently intact that, with good treat-
ment and a bit of luck, can maintain jobs and function
usefully in society. Thus, we need to find frequent and
ubiquitous factors that can affect virtually all brain func-
tions as well as creating somatic signs, but they operate in
ways that leave these functions only slightly "off kilter" as
compared to the complete disruption seen in strokes, or
classical degenerative disorders such as Alzheimer, or as
seen in Down syndrome where the behavioral pathology
is apparent from earliest stages. As we try to explain schiz-
ophrenia, we must account for most all of the develop-
mental and degenerative features of schizophrenia.
To account for the panoply of signs and symptoms seen in
schizophrenia, any complete theory of schizophrenia
must include organism wide systems. In addition to the
nervous system, the immune system and the vascular sys-
tem are defensible candidates. Both are invoked in the fol-
lowing theory: Some schizophrenia psychoses are the
result of damage to the micro-vascular system in the brain
initiated by genetically influenced abnormal inflamma-
tory processes acting in response to ubiquitous environ-
mental factors that trigger inflammatory responses,
including infection, trauma, or hypoxia. It is the relative
infrequency of the vulnerable genotypes in the popula-
tion [48] that results in only a small proportion develop-
ing overt psychosis.
We wish to emphasize that our hypothesis specifically
identifies the microvascular system as the critical site of
inflammation. We postulate that the inflamed micro-ves-
sels lose their coupling with astrocytes, leading to dis-
rupted regulation of cerebral blood flow and damage to
the blood brain barrier. These disruptions in homeostatic
mechanisms then lead to abnormal signal processing. Our
focus on inflammation of the vessels differentiates our
hypothesis from models of widespread parenchymal
inflammation such as seen in psychotic syndromes fol-
lowing, for example, encephalitis lethargica, or paraneo-
plastic syndromes. Many acute inflammatory disorders of
the brain involve inflammation of both the parenchyma
and the vasculature. By contrast, we are proposing a
chronic, smoldering, inflammation of the vessels alone.
And, finally, we distinguish our hypothesis from the the-
ories of schizophrenia implicating direct parenchymal
infection of the brain (c.f. [49]) and also differentiates our
hypothesis from speculations about schizophrenia that
invoke infectious agents altering DNA [50].
Many prior debates about inflammation in the brains of
people with schizophrenia have focused on the presence
of absence of gliosis (see [51] for review). The consensusBMC Medical Genetics 2005, 6:7 http://www.biomedcentral.com/1471-2350/6/7
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opinion is that gliosis, though present in some cases, is
not a consistent feature of the neuropathology of schizo-
phrenia. However, as Harrison [51] points out, evaluating
gliosis is fraught with a multitude of problems and is not
a definitive indicator of degenerative/inflammatory
changes in the brain. More recent efforts have demon-
strated activation of microglia in the brains of some indi-
viduals with schizophrenia implying an ongoing
immunopathological process in addition to what ever
happened early in development [52]. Ongoing neurode-
generative processes are suggested by increased levels of
S100B, a small calcium binding astrocytic protein that is
involved in inducing apoptosis and modulating proin-
flammatory cytokines [53-55].
It is likely that the current clinical syndrome of schizo-
phrenia is etiologically heterogeneous. We do not pretend
to explain all (DSM or ICD) cases of syndromal schizo-
phrenia. Instead, we put forward our hypothesis as an
attempt to define a psychiatric syndrome in terms of a par-
ticular pathophysiology. Following this course may then
help refine our nosology (see also section on 'specificity'
below) and cause us to recalculate basics 'facts' such as
prevalence rates.
Discussion
A primer on CNS blood supply
Neurons derive their energy from oxygen and glucose
delivered by the vascular system, plus lactate and glycogen
derived from astroglia [56]. The combination of neurons,
astroglia, and micro-vessels form a metabolic trio [56]
whereby the glia extend processes interacting with neu-
rons on the one hand and, on the other, form endplates
interdigitated into capillary walls. Rather than being pas-
sive conduits, the CNS vascular system is the most pre-
cisely managed and the most complex fluid dynamic
system known. Regulation of cerebral blood flow (CBF) is
managed primarily by a coupling between astrocytic glial
cells [56-59] and capillary endothelium [60-65]. Astro-
cytes sense local neuronal metabolic activity and adjust
blood flow as needed. Cerebral vessels change caliber in
response to vasoactive substances released by astrocytes
activated by glutamate receptors [56,66,67]. Serotonin
[68], acetylcholine [69] and dopamine [66,70,71] trans-
mission between astrocytes and micro vessels also play
roles. When the neuronal activation of discrete areas is
sustained over longer periods, vasoactive substances stim-
ulate angiogenesis resulting in increased capillary density
[67] thus enhancing local neuronal circuitry. Conversely,
decrease in capillary density is likely to reduce the func-
tional capacity of brain areas so affected [67]. Conse-
quently, capillary beds in the cortex are not distributed in
uniform fashion [72]. There are close relationships among
local neuronal activity, density of capillary bed, and the
distribution of valve-like flow control structures [73].
Developmentally, the CNS vascular system originates
from capillary endothelial cells that migrate into develop-
ing neuro-ectoderm under the influence of trophic factors
such as vascular endothelial growth factor (VEGF) [74]
and erythropoietin [75] both produced by astroglia. The
developing micro-vasculature, although comprising only
0.1% of the entire brain, and operating under the influ-
ence of genetic directives, has a key role in the develop-
ment, maintenance and repair of the brain [76]. In turn,
VEGF has trophic effects on neurons and glial cells, and
the activity of VEGF influenced angiogenesis is directly
proportional to the high metabolic activity of neocortical
development [77]. Thus, angiogenesis and neurogenesis
occur simultaneously and synergistically [78-80]. In addi-
tion to formation of capillaries themselves, intricate anas-
tomoses between micro-vessels further 'fine tune' the
metabolic support of developing glia and neurons [81]
The genetics of infectious & inflammatory diseases
When infectious agents give rise to inflammatory vascular
disease, the nature of the infectious agent may be less
important that an individual's genetically influenced
inflammatory response. The concept that infectious dis-
ease may have a genetic component is, of course, not new.
Many agricultural geneticists make their livings by breed-
ing disease resistance into both plants and animals
[82,83]. One of the founders of behavioral genetics, Franz
Kallmann [84], showed genetic factors influenced acquir-
ing tuberculosis (DZ concordance = 26%, MZ concord-
ance = 87%), an observation that was confirmed in
modern times [85,86]. Many other infectious diseases
appear to have genetic factors influencing susceptibility or
resistance to the infection [87-97]. Mechanisms for genet-
ically mediated responses to infection occur through
genetic variations in immune mediators such as
cytokines[96] and HLA factors [98,99].
Familial Mediterranean Fever (FMF) [100,101] provides a
heuristic Mendelian example. The gene for FMF is located
on the short arm of chromosome 16 and produces pyrin
(marenostrin) that functions in a negative feed back loop
to suppress inflammation. Absence of pyrin leads to exag-
gerated inflammatory responses. Vasculitis is one of the
consequences [102]. Additionally, very high rates of rheu-
matic fever (RF) or rheumatic heart disease (RHD) are
found in relatives of patients with FMF[103]. Having even
one mutant gene appears to lead to immune hyperactivity
to streptococcal antigens. We also know that antibody
[104] production and cytokine activity [105] in RF
patients is more marked than non-rheumatics. It is clear
that genes influence the host's response to infection. A
similar line of reasoning applies to other inducers of
inflammation such as traumatic injury [106] or hypoxia
[107,108].BMC Medical Genetics 2005, 6:7 http://www.biomedcentral.com/1471-2350/6/7
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Just as the CNS blood supply is highly regulated, the
inflammatory systems in the brain require 'fine tuning.'
Given the limited ability for adult brain to regenerate, and
assuming there is little tissue to spare, it would make sense
that the brain should be protected from overabundant
inflammatory reactions [109]. Astrocytes play a key role in
the expression of inflammatory cytokines, chemokines,
and growth factors involving the modulation of gene
expression for these factors [109-111].
Let us suppose that schizophrenia develops following an
infection (or trauma or anoxia – the environmental con-
tributors) but the host's response is determined by genetic
factors regulating the nature and degree of inflammation.
That infectious agents may be operative in schizophrenia
is supported by several of lines of evidence. Summaries
can be found in numerous sources [49,50,112-116]. The
same concept applies to trauma [106] or anoxia [79,107]
that may also stimulate inflammatory processes.
Vascular disease and psychopathology
The syndrome of schizophrenia is likely to be etiologically
heterogeneous and a multitude of CNS disorders can give
rise to schizophrenic-like psychoses [117]. The idea that
CNS micro-vascular diseases, in particular, are factors in
psychotic disorders is also an old idea [118,119] that
deserves a second look in light of new perspectives offered
by developments in the genetics of inflammatory diseases.
There are many examples of psychoses resulting from
micro-vascular CNS disease including lupus and Sjögren
syndrome [120]. Neuroimaging and neurocognitive defi-
cits in these disorders are similar to those seen in schizo-
phrenia [121]. Psychoses associated with substance abuse
are also associated with CNS vasculitis [122]. Further-
more, infectious agents such as syphilis [123] and rheu-
matic fever (RF – see below), lead to micro-vascular
disorders of the CNS that are associated with psychiatric
symptoms including psychoses. Thomas, et. al. [124] also
demonstrated small vessel abnormalities in the depressed
elderly. At the same time, there is growing interest in
cytokines and other inflammatory agents in psycho-
ses[125] as well as growing awareness that inflammatory
reactions are modulated by neuropeptides [126].
Inflammatory processes often damage the precise regula-
tion of cerebral blood flow. The wide spectrum of clinical
conditions thought to be created, in part, by inflamma-
tory CNS micro-vessel disease include Alzheimer disease
where it is thought that inflammatory processed damage
the micro-vascular endothelium causing insufficient
blood flow leading to oxidative stress, a build up of amy-
loid, and eventual cell death [127-135]. Cerebral palsy is
also conceptualized as an infectious-inflammatory-vascu-
lar disorder where the vascular lesion is complete throm-
bosis [136]. Neurotoxic effects of methamphetamine and
cocaine appear to be due to induction of inflammatory
genes in small vessel endothelial cells [122,137], thus
explaining the vascular damage seen in amphetamine and
cocaine abuse that was previously attributed to contami-
nants of injected drugs [122,138-140].
Returning to the early stages of life, we have seen that the
development of the neurons and glia are intimately asso-
ciated with, and dependent on, the parallel development
of the CNS vasculature. If the stated theory is correct, and
given the developmental perspective of schizophrenia ---
early developmental perturbations of the CNS set the
stage for later schizophrenia--- we would expect to find
support for the idea that inflammatory events early in life
affect CNS vascular function. Such is the case. Whether the
early insults are traumatic, infectious, or hypoxic; inflam-
matory process are involved in the attempts to protect and
repair by modulating angiogenesis [141-148]. Thus, the
reports implicating pregnancy and birth complications
(anoxia, trauma or maternal infections) in the develop-
ment of some cases of schizophrenia [149,150] could all
be mediated by the common pathway of inflammatory-
vascular mechanisms. Individuals who's genes created
perturbations in inflammatory-vascular regulation would
continue to experience abnormalities of protection and
repair in response to subsequent CNS insults. Over time,
the accumulation of 'hits' could lead to brain dysfunction
to the extent seen in psychoses. The greater the number
and duration of 'hits,' the greater the risk for a deteriorat-
ing /degenerative course. That neuroleptics may alter the
permeability of the blood brain barrier and modify
immunoregulation in the CNS [151] strengthens the argu-
ment for early treatment as a strategy to prevent
deterioration.
Alterations of cerebral blood flow in schizophrenia
Since the time of Seymour Kety's pioneering efforts
[152,153], there has been interest in altered cerebral
blood flow in people with schizophrenia. An in-depth
review of this large literature is beyond the scope of this
paper. The interested reader is referred to discussions of
reduced anterior cerebral perfusion leading to the concept
of 'hypofrontality' in schizophrenia [154,155] and to
more recent reviews [156-158]. Bachneff's [159] review
and theory about defects in regulation of CNS microvas-
cular systems is particularly relevant. These reviews sum-
marize a consistent body of evidence showing reduced
cerebral blood flow in brains of people with schizophre-
nia especially to anterior regions. Flow deficits are seen in
medication-naive new onset cases [160,161] and more
established cases free of neuroleptics [162] suggesting that
flow perturbations are neither the consequence of dura-
tion of illness nor treatment. Neuroleptics can alter cere-
bral blood flow [163,164] although the effects may be
regionally and drug specific [165,166]. Decreased frontalBMC Medical Genetics 2005, 6:7 http://www.biomedcentral.com/1471-2350/6/7
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flow is often associated with negative symptoms
[167,168]. In addition to the frontal cortex, flow abnor-
malities in people with schizophrenia have been noted in
the cingulate cortex [169,170], thalamus [171], basal gan-
glia [172], parietal cortex [167,170] and cerebellum
[171]. Furthermore, in some instances, flow rates are
increased [160,170]. Rather than a simple hypothesis of
hypofrontality in schizophrenia, theorizing is evolving
toward a concept of "dysfunctional circuits"[160] or "inef-
ficient dynamic modulation" [173] of cerebral metabo-
lism which is supported by other examples of abnormal
modulation of cerebral blood flow in response to activa-
tion tasks [171,174]. Disturbances of blood flow in schiz-
ophrenia are well documented but are not limited to
schizophrenia. Disturbed cerebral blood flow is also
reported in obsessive compulsive disorder [175] and
depression [176,177] as well as in Alzheimer disease
(cited earlier). The usual interpretation is that alterations
of blood flow arise as a consequence of abnormal neuro-
nal metabolism. The theory proposed by this paper turns
the causal arrow around to suggest that abnormalities of
blood flow lead to altered neuronal-glial function that, in
turn, leads to psychopathology. There has been scant
direct visualization of the vascular system in schizophre-
nia, but at least one laboratory has found evidence of
atypically simplified angioarchitecture and failure of nor-
mal arborization of small vessels [32].
Post- streptococcal behavioral syndromes as a model
Post-streptococcal neuropsychiatric syndromes include
Syndenham chorea, the PANDAS/obsessive compulsive
syndrome, tics including Tourette syndrome, and possi-
bly, ADHD [178-184]. Psychotic disorders are also impli-
cated [183,185] and see citations below.
Sydenham chorea is the best-known neuropsychiatric
complication following streptococcal pharyngitis. The
association of psychoses and Sydenham chorea as well as
with RF even in the absence of chorea, was discussed in
the 17th and 18th centuries starting with Sydenham him-
self (see [186]). The interest in psychoses associated with
RF continued throughout the 1900's [187-197]. People
with a history of Sydenham chorea and/or rheumatic fever
are at high risk for developing psychopathology later in
life [198,199] with a relative risk for schizophrenia as high
as 8.9 in a 10 year follow-up of 29 Sydenham patients
[200]. There is a suggestion that the family members of
Sydenham patients are also at higher risk for psychosis
[201].
During the 1940's-1960's when RF was still quite preva-
lent, people with psychoses appeared to have higher than
expected rates of histories of RHD or RF)[195,202,203] or
rheumatic chorea [204]. Psychotic patients with RHD
more often had early (<age 19) onset, movement disor-
ders, progressively insidious courses and poor long-term
outcomes [203]. Preliminary data from a Minnesota study
also finds increased rates of RHD in psychotic patients, a
pattern of increased psychiatric hospitalization following
an epidemic of RF, and a clinical course for "rheumatic
psychoses" that disproportionately led to a severe and
continuous decline in function [205]. Although schizo-
phrenia-like psychoses were the most common psychopa-
thology related to rheumatic syndromes, manic-
depressive, involutional, and senile psychoses were also
observed [183,197].
An inflammatory reaction of the CNS vascular endothe-
lium (vasculitis) is a common denominator in the both
acute and chronic cerebral consequences of rheumatic
fever. [186,187,190,195,197,206-209]. The microvascu-
lar lesions suggest both an obliterating process likely due
to micro-emboli from rheumatic cardiac valves and an
inflammatory process involving irregular proliferative
changes in the vascular endothelium, dilatation of the
lymphatic spaces surrounding the capillaries suggesting
increased permeability of the capillary endothelium, and
inflammatory cell infiltrates. Disruption of the blood
brain barrier suggested by the evidence of increased per-
meability of the small vessels could compromise the
immunological protection of the brain leading to the for-
mation of the anti-neuronal antibodies seen in post-strep-
tococcal CNS syndromes. In parallel fashion, people with
schizophrenia show evidence of altered blood brain bar-
rier and consequent alterations in immunological mark-
ers [210]
The post-strep psychopathologies provide a precedent for
the hypothesis of this paper by demonstrating that an
infectious process can trigger a series of inflammatory
reactions that lead to a variety of somatic and psychiatric
syndromes, including psychoses where vascular pathol-
ogy is implicated. The pathogenicity of a strep infection is
a function of the strain (genotype) of the bacterium and
the genetically mediated inflammatory mechanisms of
the host [211] and illustrates how a ubiquitous and often
relatively benign environmental factor can create more
serious sequelae in a limited number of genetically predis-
posed individuals-true genotype by environment
interaction.
Summary
The ideas here are not completely new. Eugen Bleuler [14]
remarked: "The fragility of the blood vessels which
appears in many schizophrenics, both acute and chronic,
seems to indicate a real vascular pathology (p.167)." We
bring old ideas forward into the light of new understand-
ings offered by molecular genetics and inflammatory dis-
eases. Since the late 1800's there has been evidence of
inflammatory neuro-vascular abnormalities in psychiatricBMC Medical Genetics 2005, 6:7 http://www.biomedcentral.com/1471-2350/6/7
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illness that were initiated by infectious agents. CNS lues
(syphilis) is the best-known example. This paper expands
the concept to suggest that a variety of environmental
insults (infection, trauma, anoxia) may follow a common
final pathway to psychopathology by stimulating inflam-
matory processes that damage the capillary-glial-neuron
triad as illustrated in Figure 1.
Abnormal behaviors develop as a result of disruptions in
astroglial mediated coupling of cerebral blood flow to
neuronal metabolic needs. These subtle disruptions are
hard to find, as the microvasculature comprises only
about 0.1% of the brain and are of a scale more appropri-
ate for electron microscopy. None-the-less, the hemody-
namic perturbations have sufficient impact to cause subtle
but widespread disruption of the normally harmonious
coordination of CNS function leading to a condition var-
iously conceived as a "neurointegrative defect"[212],
"synaptic slippage" [213], "abnormal signal transduction"
[4], "inefficient dynamic modulation" [173] or "synaptic
destabilization" [214]. The ultimate impact would lead to
psychopathology including psychoses as the vascular-
glial-neuron triad is progressively damaged over time after
repeated inflammatory episodes. The resultant failure to
regulate the delivery of oxygen and energy adequately
would lead to oxidative stress [215-217]. Oxidative stress,
in turn, can further damage the microvasculature and the
blood brain barrier [218-220]. The astroglial-capillary
Simplified schematic illustrating the interconnected vascular-glial-neuron triad and how inflammatory processes may disrupt  normal function Figure 1
Simplified schematic illustrating the interconnected vascular-glial-neuron triad and how inflammatory processes may disrupt 
normal function.
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partnership that protects the integrity of the blood brain
barrier would be compromised, thus exposing neural
tissue to damage from immunological attack [221].
Known precedents of such processes are found in the
behavioral changes seen in CNS vascular inflammatory
diseases such as lupus and the post-strep syndromes
described above.
This theory could explain how developmental events such
as prenatal infections [150,222], and other birth and preg-
nancy complications [149] including anoxia [223] are
linked to later schizophrenia – infection, trauma, or
anoxia all stimulate inflammatory processes [224]. The
data suggesting an (statistical) influence of season of birth
[116] is also consistent with the hypothesis as infectious
epidemics often follow seasonal patterns. Some of the
minor physical anomalies such as unusual scalp hair pat-
terns and dermatoglyphic changes are explained because
the development of these phenomena are linked to each
other [225], to the development of the central nervous
system [226], and are developmentally modulated by the
pleiotropic effects of the same substances that modulate
brain vascular development (e.g., vascular endothelial
growth factor/vascular permeability factor [227] and epi-
dermal growth factor [228]). The waxing and waning of
symptoms would correspond to waxing and waning of
inflammations as individuals are exposed, recover, and
then re-exposed in conjunction with other physiological
and hormonal influences, as seen in lupus [229]. The
nature and severity of symptoms would depend on where
in the brain the inflammation takes place and this may be
stochastic. As the micro- vascular system is everywhere in
the brain, lesions could produce the variety of symptoms
seen in schizophrenia including dysfunctions of thought,
emotion, memory, motor skills and autonomic regula-
tion. The developmental age of the individual will also
make a difference. Inflammatory processes that alter ang-
iogenesis during prenatal development will likely have
more dire consequences than inflammatory reactions that
start after CNS maturation although even the adult brain
remains susceptible [230]. We have attempted to sche-
matically illustrate this dynamic process in Figure 2.
This theory also captures many of the little oddities
observed in schizophrenia. For example, the reported
abnormalities of the nail fold capillary beds seen in some
people with schizophrenia [44] are also seen in people
with inflammatory disorders such as FMF [231] and rheu-
matoid arthritis [232]. Another oddity is the negative
association between schizophrenia and rheumatoid
arthritis [45]. There are parallels in the post-streptococcal
syndromes where RF and acute post-streptococcal glomer-
ulonephritis very rarely occur in the same patient [233].
Some strains of group-A-streptococci identified by their
M-protein serotypes are rheumatogenic while others are
nephritogenic [233,234]. Phage or phage-like elements
inserted into the streptococcal DNA are a major source of
variation between streptococcal strains and these ele-
ments determine pathogenicity [235]. Additionally, host
variation in humoral and cellular immune response shape
the outcome of infection[211] By analogy, individuals
with vascular/CNS involvement following, for example,
streptococcal infections may be systematically spared
from joint involvement as a function of both the invading
strain and the individuals susceptibilities. Alternatively, as
postulated for Alzheimer disease (cited earlier) that is also
less common in people treated for arthritis, the anti-
inflammatory treatments for arthritis might reduce the
risk of inflammatory brain disease.
Another line of evidence compatible with this theory is
the observation that genetic linkages for schizophrenia
coincide with sites for glial growth factor cell regulators
[214] and, as we have seen, the glia are key intermediaries
of CNS inflammation and vascular regulation. More spe-
cifically, emerging data demonstrate associations between
schizophrenia and genetic polymorphisms in regulators
of inflammation such as tumor necrosis factor alpha
genes [236,237] and interleukin-1 genes [238]. Another
piece that fits into the puzzle is the fact that neuroleptics
have inflammatory modulating properties [239-244] and
neuroleptic treatment may be synergized by addition of
anti-inflammatory drugs [245].
It may well be that the environmental components of psy-
chiatric illness such as schizophrenia are relatively minor,
ubiquitous, or chance events [246,247] that have the
potential to stimulate the inflammatory systems. How-
ever, the nature of the insults may be less important than
individuals' genetically influenced and idiosyncratic
responses to the insults, similar to individuals with FMF
who have an exaggerated inflammatory response. Thus,
the genetic components of the inherited predisposition to
mental illness may lie "upstream" in the immune system
rather than in the CNS per se. The possibility that the envi-
ronmental agents may be nearly universal (e.g. who has
not had a strep throat or viral syndrome?), will mean that
the prevalence of the etiological factor will be similar in
control and experimental groups thus making it too easy
to dismiss key environmental factors in null hypothesis
designs [47,248]. Rather than focus on the environmental
contributors that could be non-specific and ubiquitous, it
will be more productive to look for genotypes that
respond abnormally to triggers of inflammation and
microvascular dysfunction (cf[48]). These individuals
would be the ones who are at high risk for psychiatric ill-
ness. However, the inflammatory processes involve a cas-
cade of steps involving many genes. But this, too, fits with
the polygenic features of schizophrenia [249]. Identifica-
tion of high-risk individuals, combined with such tools asBMC Medical Genetics 2005, 6:7 http://www.biomedcentral.com/1471-2350/6/7
Page 9 of 17
(page number not for citation purposes)
Schematic illustration of how inflammatory processes, from conception onward, may lead to CNS damage or dysfunction that  dynamically alters the epigenetic landscape (reaction surface) thus affecting the liability for developing schizophrenia Figure 2
Schematic illustration of how inflammatory processes, from conception onward, may lead to CNS damage or dysfunction that 
dynamically alters the epigenetic landscape (reaction surface) thus affecting the liability for developing schizophrenia. Blue 
planes intersecting the reaction surface indicate levels of liability above which symptoms become manifest. Measurable factors 
in the middle of the figure are good candidates for endophenotypes. Adapted from [261,262].
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immunizations or anti-inflammatory agents may pro-
mote prevention of much psychiatric morbidity. Already,
the cytokine regulator and vascular growth factor erythro-
poietin is suggested as a possible neuroprotective factor in
schizophrenia [250]
Future directions
The speculations about psychoses developing from vascu-
lar/inflammatory processes provide direction for future
research across many domains. In addition to pursuing
direct evidence of altered activities in inflammatory/
immune systems in people with psychoses, the inflamma-
tory/vascular theory has implications for epidemiology,
genetics, neuroimaging and neuropathology. For the epi-
demiologist, the challenge will be to detect relatively
small signals against a very noisy background. We hypoth-
esize that the triggers for inflammation can be many and
varied and are common factors in the environment. Imag-
ine starting with the clinical syndrome of Sydenham cho-
rea and comparing the rates of strep throat in those
affected vs. comparison sample of people without Syden-
ham chorea. Null hypothesis testing with small sample
sizes and nearly ubiquitous etiological agents are clearly
not adequate. A second epidemiological challenge is to
cast a broad enough net to capture the wide variety of pos-
sible contributing factors. Rather than taking a one by one
approach to exploring the etiological contributions of,
say, virus titers, anoxia, physical trauma, the epidemiolo-
gist should look for any and all. It would be predicted that
individuals with multiple "hits" (e.g. in utero exposure to
virus and low Apgar scores and childhood head trauma)
would be at greater risk than those exposed to just one
event. If in utero inflammatory processes are active in the
genesis of schizophrenia we would also predict an
increased rate of fetal deaths in families of schizophrenic
probands. A third epidemiological opportunity lies in the
search for non-psychiatric inflammatory-related disease
or traits in people with psychosis. If something is askew in
the inflammatory process in schizophrenia, the effects
will show up in other parts of the body. Though requiring
replication, the association of psychosis with hemolytic
anemia in lupus [251] provides an illustrative example. In
addition to rheumatoid arthritis, the associations of dia-
betes and cancer have been explored in schizophrenia;
one of is exploring rheumatic heart disease [205]. Popula-
tion-based health registries should be used in a search for
co-morbid physical illness.
For geneticists, the proposed theory obviously points to
linkage/association studies using inflammation genes; a
few examples were cited previously [236-238]. A simple
step with extant data might start with a meta analysis
defining chromosomal "hot spots" for linkage with schiz-
ophrenia and search the gnome maps for immune regula-
tors at these sites as Moises, et al [214] have done for glial
growth regulators. Family, twin, and adoption methodol-
ogies can all be applied to the issue of co-morbid or co-
segregating physical conditions.
The inflammatory/vascular theory has much to suggest to
neuroimaging research especially in the realm of reinter-
preting regional perturbations in metabolic activity as pri-
mary disturbances of flow regulation rather than intrinsic
neuronal metabolic abnormalities. It would be interesting
to assess the impact of vasoactive compounds and inflam-
matory modulators on neuroimaging studies of regional
blood flow. Likewise, further pursuit of neuroimaging evi-
dence of disrupted blood brain barrier, as initiated by
Dysken, et al [252], and with manipulation of inflamma-
tory systems as suggested by Mueller and Ackenheil [253]
would test our hypothesis.
The neuropathology of schizophrenia, focused mostly on
the neurons, is notable for inconsistencies in findings (see
[51,254] for reviews). Such inconsistency is exactly what
would be predicted by an inflammatory/vascular theory
where the lesions are truly functional in the sense that the
function of the brain alters in relation to perturbations in
blood flow regulation. Only the more prolonged and seri-
ous inflammation will leave visible traces of neuronal
damage and such damage may be patchy and inconsistent
from one patient to another. However, over the early years
of CNS development, alterations in cellular organization
or migration may result from disrupted angiogensis that
must go hand in hand with neuronal and glial develop-
ment. The location and extent of CNS change will be a
function of severity of inflammation and timing during
development. Such consequences will be hard to demon-
strate in human post-mortem tissues and animal or in
vitro models may be more fruitful areas for study the
effects of inflammation on neurogenesis and blood flow
regulation. To our knowledge, human post mortem stud-
ies have not utilized vascular cast methodology and this
should be considered, perhaps casting one half of a speci-
men brain while subjecting the other half to cellular
analysis.
Specificity
Because of our interests and expertise, we have focused
our attention on schizophrenia as the behavioral pheno-
type resulting from inflammatory-vascular pathology but
the theory presented here is likely to be more general.
Indeed, our use of examples of psychoses associated with
known inflammatory- vascular pathologies (e.g. autoim-
mune CNS vascular disease or infectious CNS vascular
disease as seen in syphilis) makes it clear that a vascular-
inflammatory theory may apply to a wide range of psy-
chotic conditions that may also include psychoses associ-
ated with mood disorders. Whereas, the classical genetic
studies support the separateness of schizophrenia andBMC Medical Genetics 2005, 6:7 http://www.biomedcentral.com/1471-2350/6/7
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mood disorders [255], there are modern molecular signs
that schizophrenia and mood disorders share genetic ele-
ments in common [256,257]. Furthermore, mood disor-
ders, like schizophrenia, show evidence of frontal lobe
pathology, enlarged ventricles, abnormal cerebral blood
flow [33,258] and vascular abnormalities [124]. To what
extent all of these changes are epiphenomena of being
psychotic (treatment effects or stress, etc) remain debata-
ble [259].
However, finding similar brain changes in a variety of psy-
chotic conditions does not necessarily mean these
changes are epiphenomena. Examples from neuropsychi-
atry teach us that the underlying pathology does not nec-
essarily define the behavioral symptoms. Thus, psychoses
with Huntington disease may be affective-like or schizo-
phreniform. Similar pathophysiological mechanisms may
underlie a variety of psychotic phenotypes. The evolution
of behavioral symptoms for any given pathophysiology
may depend on a variety of moderating variables such as
an individual's developmental age when the disease proc-
ess begins, gender, hormones, genetic 'landscape' upon
which the disease process unfolds, along with the nature,
frequency, and intensity of successive triggers of inflam-
matory response.
Reprise
A broad spectrum of observations leads to a working
hypothesis that schizophrenia and, possibly, other psychi-
atric syndromes are the result of genetically mediated
inflammatory reactions that damage the neuron-glial-cap-
illary triad with resultant loss of ability to fine tune
regional brain metabolism. This hypothesis incorporates
genetic, epigenetic [260], and environmental factors. Fur-
thermore, an inflammatory/vascular theory can explain
the variety of behavioral symptoms seen in schizophrenia,
the variable course of the illness, and the numerous other
puzzling observations such as an excess of minor physical
anomalies. Should this theory prove heuristic, it would
point to the use of inflammatory modulators in treating
the illness. Perhaps more importantly, identifying indi-
viduals who were at high risk for the disorder in high
genetic risk families as well as the general population,
because of abnormalities of their inflammatory systems,
holds hope for prevention through early intervention
using inflammatory modulators.
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